Citation Information :
Suvarna S, Dutt P, Misra A, Usmani N, Suvarna C. Intricate Assessment and Evaluation of Dental Implants in Patients on Bisphosphonate Therapy: A Retrospective Analysis. J Contemp Dent Pract 2016; 17 (5):414-417.
Osteonecrosis is one of the prevalent side effects of bisphosphonate (BP) therapy in oral cancer patients. In case of patients with various oncologic lesions, standard guidelines contraindicate the use of dental implants if the patients are on BP therapy. Literature also quotes studies that emphasize on the safety of dental implants in patients on BP therapy. Hence, this study aimed to retrospectively evaluate the clinical outcome of dental implants in patients on BP therapy.
Materials and methods
In this retrospective analysis, a total of 140 dental implants in 112 patients were included. Inclusion criteria included only those patients who were on or had history of BP therapy. Calculation of implant failure and survival rate was done.
Results
Ten cases of implant failure occurred, giving a success rate of above 92%, which was comparable to the results found in previous studies in patients who were not on BP therapy.
Conclusion
No significant risk of implant failure is seen in patients on BP therapy compared with other patients.
How to cite this article
Suvarna S, Dutt P, Misra A, Usmani N, Singh A, Suvarna C. Intricate Assessment and Evaluation of Dental Implants in Patients on Bisphosphonate Therapy: A Retrospective Analysis. J Contemp Dent Pract 2016;17(5):414-417.
Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamentenassoziierte Kiefernekrosen; 2012. AWMF online.
Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 2010 Jul;6:11.
Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005 Nov;63(11):1567-1575.
Oral implants in patients receiving bisphosphonates: A review and update. Med Oral Patol Oral Cir Bucal 2008 Dec;13(12):E755-E760.
Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007 Jul;65(7):1328-1331.
Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004 May;62(5):527-534.
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003 Sep;61(9):1115-1117.
Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann NY Acad Sci 2011 Feb;1218(1):47-54.
Dental implants in patients treated with antiresorptive medication – A systematic literature review. Int J Implant Dent 2016 Apr;2:1-15.
Oral bisphosphonates and dental implants: A retrospective study. J Oral Maxillofac Surg 2008 May;66(5):1022-1024.
Bisphosphonates and osteonecrosis of jaws. J Indian Acad Oral Med Radiol 2012;24(4):330-333.
Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History etiology, prevention, and treatment. 2nd ed. New Malden: Quintessence Publishing Co, Inc.; 2007. p. 9-93.
Bisphosphonate-related osteonecrosis of the jaw and dental implants. J Istanbul Univ Fac Dent 2016;50(1):59-64.
Influence of bisphosphonates on alveolar bone loss around osseointegrated implants. J Oral Implant 2011 Jun;37(3):335-346.
